The Moment Most Issuers Miss
Most officers who sign toxic financing agreements do not realize what they have signed until the first conversion cycle begins. The note looked manageable at execution — a fixed principal amount, a stated interest rate, a maturity date. What they did not fully model was the conversion mechanics. By the time the financing source begins converting, the share count has expanded dramatically, the stock price has declined in response to the dilution, and the conversion price has ratcheted down to reflect the lower price — triggering further conversions at an even lower price. The cycle is self-reinforcing and, once started, extremely difficult to stop.
The provisions that create this outcome are not hidden. They are in the agreement. The problem is that most issuers and their counsel do not identify them as the existential threats they are before signing.
Seven Provisions That Should Stop Any Issuer
1. Variable Conversion Price Tied to Market Price
Any conversion provision that calculates the conversion price as a percentage of the market price — typically 50 to 75 percent of the lowest closing price over a lookback period — is a death spiral mechanism. The lower the stock price falls, the more shares the financing source receives per dollar of principal converted. This creates a direct incentive for the financing source to short the stock, and it means the issuer cannot predict how many shares will ultimately be issued. Before signing any convertible note, confirm that the conversion price is fixed at execution. If it is not, the agreement should be reviewed with extreme caution.
2. Lookback Periods for Conversion Price Calculation
Even agreements that appear to have a fixed conversion price sometimes include a lookback provision that resets the conversion price to the lowest trading price over a specified period — commonly 10, 20, or 30 trading days. A 30-day lookback means the conversion price will always reflect the lowest point of the stock's recent trading range, not its current price. This is functionally equivalent to a variable conversion price and carries the same enforcement and dilution risks.
3. Ratchet-Down Anti-Dilution Provisions
Ratchet-down anti-dilution provisions reduce the conversion price whenever the issuer issues new shares at a price below the current conversion price. In practice, this means that any subsequent financing — even a routine equity raise — can trigger a reduction in the conversion price on the outstanding convertible note, accelerating the dilution spiral. Issuers that enter into these arrangements and then attempt to raise additional capital frequently find that the ratchet provision makes subsequent financing prohibitively dilutive.
4. Default Provisions That Increase Principal
Many toxic financing agreements include default provisions that increase the outstanding principal balance by 25 to 50 percent upon the occurrence of specified events — failure to maintain current SEC filings, failure to maintain a minimum trading volume, failure to maintain the effectiveness of a registration statement covering the resale of conversion shares, or a decline in the stock price below a specified floor. These provisions are often triggered within the first several months of the agreement, before the issuer has had any opportunity to remediate the underlying condition. The result is a substantially larger debt obligation than the issuer originally incurred.
5. Prepayment Penalties That Eliminate the Exit
Issuers that recognize the danger of a toxic financing arrangement often attempt to repay the note early to stop the conversion cycle. Toxic financing agreements routinely include prepayment penalties of 25 to 50 percent of the outstanding principal, making early repayment economically equivalent to accepting the dilution. This provision is designed to eliminate the issuer's ability to exit the arrangement once the conversion cycle has begun. Before signing, confirm whether the note can be prepaid at par and on what timeline.
6. Most Favored Nation Clauses
Most favored nation clauses require the issuer to offer the financing source the benefit of any more favorable terms granted to subsequent investors. If the issuer later raises capital on terms that include a lower conversion price, a higher interest rate, or additional security, the financing source is entitled to those same terms. This provision effectively prevents the issuer from improving its capital structure without simultaneously improving the terms of the existing toxic financing arrangement.
7. Registration Rights With Penalty Provisions
Most toxic financing agreements require the issuer to register the resale of the shares issuable upon conversion within a specified period — typically 30 to 90 days. Failure to meet this deadline triggers penalty provisions that increase the outstanding principal or reduce the conversion price. Maintaining an effective registration statement requires ongoing SEC compliance, and any lapse — a missed filing deadline, a restatement, a comment letter that delays effectiveness — can trigger the penalty. Issuers with any history of SEC compliance issues should treat this provision as a near-certain default trigger.
What Securities Counsel Should Do Before Execution
The review of a convertible financing agreement is not a standard contract review. It requires modeling the full dilutive impact of the conversion provisions across a range of stock price scenarios — including scenarios where the stock price declines significantly from its current level. It requires identifying every provision that can accelerate the conversion schedule, reduce the conversion price, or increase the outstanding principal. And it requires an honest assessment of whether the issuer can satisfy the ongoing compliance obligations that the agreement imposes.
If the modeling reveals that the agreement could result in the issuance of shares representing more than 20 percent of the outstanding share count, the issuer's board should understand that consequence before approving the transaction. If the modeling reveals that a 50 percent decline in the stock price would result in the issuance of shares representing the majority of the outstanding share count, the board should understand that as well.
The goal of pre-execution review is not to find a reason to decline the financing. It is to ensure that the officers and directors who approve the transaction understand what they are approving. That understanding is the foundation of defensible disclosure — and the absence of it is the foundation of an SEC enforcement action.
If you are evaluating a convertible financing arrangement or have already entered into one and are concerned about its terms, contact Frederick M. Lehrer, P.A. at [email protected] for a review.
Frederick M. Lehrer served as an enforcement attorney in the SEC's Division of Enforcement at the Southeast Regional Office from 1991 through 2000, and concurrently as a Special Assistant United States Attorney in the Southern District of Florida from 1997 through 1999, prosecuting securities-related financial crimes. He has practiced securities and corporate law in private practice for more than twenty-five years, advising issuers worldwide on SEC registration, disclosure obligations, Regulation D private placements, Regulation A offerings, and going public transactions. The firm is based in Florida and serves clients internationally.